Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy

Sylvain Ladoire; David Enot; Fabrice Andre; Laurence Zitvogel; Guido Kroemer

doi:10.1080/2162402X.2015.1082706

Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy

Oncoimmunology. 2015 Aug 31;5(2):e1082706. doi: 10.1080/2162402X.2015.1082706. eCollection 2016 Feb.

Authors

Sylvain Ladoire¹, David Enot², Fabrice Andre³, Laurence Zitvogel⁴, Guido Kroemer⁵

Affiliations

¹ Department of Medical Oncology, Georges François Leclerc Center,Dijon, France; Institut National de la Santé et de la Recherche Médicale, Avenir Team INSERM, CRI-866 University of Burgundy, Dijon, France; Institut National de la Santé et de la Recherche Médicale, U1015, Equipe labellisée Ligue Nationale Contre le Cancer, INSERM U1015, Institut Gustave Roussy, Villejuif, France.
² Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus , Villejuif, France.
³ Department of Medical Oncology and Breast Cancer Group, Institut Gustave Roussy, Villejuif, France; INSERM U981 "Identification of molecular predictors and new targets for cancer treatment," INSERM U981, Institut Gustave Roussy, Villejuif, France.
⁴ Institut National de la Santé et de la Recherche Médicale, U1015, Equipe labellisée Ligue Nationale Contre le Cancer, INSERM U1015, Institut Gustave Roussy, Villejuif, France; University of Paris Sud XI, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT), Villejuif, France.
⁵ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France; Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; INSERM, U1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.

Abstract

It is well established that the anticancer immune response determines the success of anthracycline-based adjuvant chemotherapy of breast cancer. This effect is in part due to the capacity of anthracyclines to induce immunogenic cell death (ICD), a cell death modality that is preceded by autophagy and followed by HMGB1 release. Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.

Keywords: Breast cancer; histology; HMGB1; immunogenic cell death; LC3B; p62; SQSTM1.